Clinical Trial Update: Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study of NRX 195183 in patients with relapsed or refractory acute promyelocytic leukemia; the trial status is unk…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Promyelocytic Leukemia

Drugs mentioned

• NRX 195183

Snippet

Sponsor: NuRx Pharmaceuticals, Inc. | Conditions: Acute Promyelocytic Leukemia | Phase 2 | Status: UNKNOWN